Announcements Trials
Browse Landscape

Phase

Phase 4 15Phase 3 10Phase 2 8Phase 1 8Phase EARLY_PHASE1 2Phase 1/2 2Phase NA 1Phase 2/3 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Melanoma 1Leukoplakia 1Leukokeratosis, Hereditary Mucosal 1

Interventions

pembrolizumab 81Nivolumab 55Ipilimumab 44Cyclophosphamide 38aldesleukin 26Interleukin-2 25fludarabine 17Temozolomide 17fludarabine phosphate 16trametinib 11dabrafenib 11Radiotherapy 11Biopsy 11avelumab 10Paclitaxel 9spartalizumab 8cemiplimab 8Dacarbazine 8Cisplatin 8Bevacizumab 8sargramostim 7binimetinib 7Fluorouracil 7poly ICLC 6lenvatinib 6epacadostat 6atezolizumab 6Magnetic Resonance Spectroscopy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Imiquimod × Dermatologic × Clear all
NCT07210775 2026-03-04

Topical Imiquimod Treatment of Oral Dysplasia

University of Southern California

Phase 1/2 Recruiting
20 enrolled
DermatologicHead & Neck

Leukoplakia, Leukokeratosis, Hereditary Mucosal

NCT01191034 2019-03-12

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 1/2 Terminated
2 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡